Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,114 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo 40 mg Clear all
Completed Phase 2 Interventional

A Study of NE3107 in Early Parkinson's

NCT06757010
View directory record Official record
Conditions
Parkinsons Disease (PD)
Interventions
NE3107, Placebo
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Farmington Hills, Michigan • Amherst, New York • Morrisville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

NCT04707313
View directory record Official record
Conditions
Obesity
Interventions
Placebo (Cohorts 1 and 2), PF-06882961 (Cohorts 1 and 2), Placebo (Cohort 3), PF-06882961 (Cohort 3)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
27
States / cities
Anniston, Alabama • Anaheim, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274

NCT01193062
View directory record Official record
Conditions
Healthy
Interventions
PF-04995274
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

N-acetylcysteine and NMDA Antagonist Interactions

NCT00611897
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
N-acetylcysteine and ketamine, placebo and ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 2, 2026, 6:50 PM EDT
Terminated Early Phase 1 Interventional

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

NCT03507374
View directory record Official record
Conditions
Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 2, 2026, 6:50 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

NCT02596893
View directory record Official record
Conditions
Crohn Disease
Interventions
GED-0301, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
150
States / cities
Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 2, 2026, 6:50 PM EDT
Active, not recruiting Phase 4 Interventional

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

NCT03953300
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Results available

Duloxetine Versus Pregabalin for Alcohol Dependence

NCT00929344
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Pregabalin, Duloxetine, Standardized behavioral therapy, Placebo
Drug · Behavioral
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating Simvastatin's Potential Role in Therapy

NCT00486044
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simvastatin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 69 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

NCT01826487
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Interventions
Ataluren, Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
7 Years to 16 Years · Male only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Sep 2, 2026, 6:50 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome

NCT05098509
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
RAD011, Placebo
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

NCT01030575
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions
Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
12 Hours to 72 Hours
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 2, 2026, 6:50 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8

NCT00218036
View directory record Official record
Conditions
Cocaine Abuse, Opiate Dependence
Interventions
Modafinil 200mg, Modafinil 400mg, Citalopram 20mg, Citalopram 40mg, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
22 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Results available

Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)

NCT01988571
View directory record Official record
Conditions
Breast Cancer, Lymphoma
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 100 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
51
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Sep 2, 2026, 6:50 PM EDT
Withdrawn Phase 3 Interventional

AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis

NCT01030328
View directory record Official record
Conditions
Coronary Atherosclerosis
Interventions
Placebo, TriLipix
Drug
Lead sponsor
Piedmont Healthcare
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Not applicable Interventional Results available

Vilazodone for Menopausal Hot Flashes

NCT01680900
View directory record Official record
Conditions
Hot Flushes
Interventions
vilazodone, placebo capsules
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 2, 2026, 6:50 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT01892722
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 6:50 PM EDT
Terminated Phase 1 Interventional

Effects of Propranolol on Responses to Drug-Related Imagery Scripts

NCT00688805
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Propranolol, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 3 Interventional Results available

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

NCT00849901
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine, Placebo, fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
24
States / cities
Costa Mesa, California • Irvine, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 4 Interventional Results available

A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy

NCT00785512
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 79 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
26
States / cities
Chandler, Arizona • Phoenix, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine as a Supplement to Naltrexone in Treating Heroin Dependence

NCT00476242
View directory record Official record
Conditions
Opioid Dependence, Heroin Dependence
Interventions
Vivitrol, memantine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Results available

Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder

NCT02537873
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Lorcaserin, Cocaine Intravenous (IV), Placebo comparator
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 59 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 2, 2026, 6:50 PM EDT
Terminated Phase 2 Interventional

Green Tea Extract: a Non-Surgical Alternative for Treatment of Uterine Fibroids

NCT01311869
View directory record Official record
Conditions
Leiomyoma
Interventions
EGCG ( Green Tea extract), Brown rice pills
Dietary Supplement
Lead sponsor
Meharry Medical College
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Sep 2, 2026, 6:50 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Octreotide in Severe Polycystic Liver Disease

NCT00426153
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain
Interventions
Octreotide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Sep 2, 2026, 6:50 PM EDT